Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behcet's disease: A randomised trial (Retraction in: Lancet (2000) 356:9238 (1292))

Lancet

Volumn 355, Issue 9204, 2000, Pages 605-609

  Demiroglu, Halûk ^a   Özcebe, Osman I ^a   Barista, Ibrahim ^a   Dündar, Semra ^a   Eldem, Bora ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BENZATHINE PENICILLIN; COLCHICINE;

ABDOMINAL CRAMP; ADULT; ALOPECIA; ARTHRITIS; ARTICLE; BEHCET DISEASE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; EYE DISEASE; FEMALE; FLU LIKE SYNDROME; HERPES SIMPLEX VIRUS 1; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; THROMBOCYTOPENIA; VISUAL ACUITY; VOMITING;

EID: 0034685156     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)05131-4     Document Type: Article

References (32)

1. Kaklamani V.G., Vaiopoulos G., Kaklamanis P.G. Behçet's disease. Semin Arthritis Rheum. 27:1998;197-217.
2. Eglin R.P., Lehner T., Subak-Sharpe J.H. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. Lancet. ii:1982;1356-1360.
3. Kaneko F., Takahashi Y., Muramatsu Y., Miura Y. Immunological studies on aphthous ulcer and erythema nodosum-like eruptions in Behçet's disease. Br J Dermatol. 113:1985;303-312.
4. Mizushima Y. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease: a multicenter study. J Rheumatol. 16:1989;506-511.
5. Lehner T. State of the art in Behçet's disease. Hamza M. Behçet's disease. 1997;7-14 Pub Adhoua, Tunis.
6. Matsumura N., Mizushima Y. Leucocyte movement and colchicine treatment in Behçet's disease. Lancet. ii:1975;813.
7. Haznedaroglu I.C., Demiroglu H., Özcebe O.I., Özdemir O., Dündar S.V. Benzathine penicillin in the prophylaxis and treatment of Behçet's disease. Boki K.A., Drosos A.A., Moutsopoulos H.M., Tzioufas A.G., Vlachoyiannopoulos P.G. Proceedings of the Seventh Mediterranean Congress of Rheumatology. 1994;185-188 Monduzzi Editore, Athens, Bologna.
8. Kaneko F., Oyama N., Nishibu A. Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J. 38:1997;444-454.
9. Çalgüneri M., Ertenli I., Kiraz S., Erman M., Çelik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology. 192:1996;125-128.
10. Çalgüneri M., Kiraz S., Ertenli I., Benekli M., Karaarslan Y., Çelik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease: a randomized clinical trial. Arthritis Rheum. 39:1996;2062-2065.
11. Hijikata K., Masuda K. Visual prognosis in Behçet's disease: effects of cyclophosphamide and colchicine. Jpn J Ophthalmol. 22:1976;506-519.
12. Sakane T., Takeno M., Suzuki N., Inaba G. Behçet's disease. N Engl J Med. 341:1999;1284-1291.
13. Tsambaos D., Eichelberg D., Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 278:1986;335-336.
14. Feron E.J., Rothova A., van Hagen P.M., Baarsma G.S., Suttorp-Schulten M.S.A. Interferon-α2b for refractory ocular Behçet's disease. Lancet. 343:1994;1428.
15. Hamuryudan V., Moral F., Yurdakul S.et al. Systemic interferon α2b treatment in Behçet's syndrome. J Rheumatol. 21:1994;1098-1100.
16. Alpsoy E., Yilmaz E., Basaran E. Interferon therapy for Behçet's disease. J Am Acad Dermatol. 31:1994;617-619.
17. Azizlerli G., Sarica R., Köse A.et al. Interferon alfa-2a in the treatment of Behçet's disease. Dermatology. 192:1996;239-241.
18. Georgiou S., Monastirli A., Pasmatzi E., Gartaganis S., Goerz G., Tsambaos D. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J Intern Med. 243:1998;367-372.
19. 2a: a pilot study. Br J Ophthalmol. 82:1998;488-494.
20. O'Duffy J.D., Calamia K., Cohen S.et al. Interferon-α treatment of Behçet's disease. J Rheumatol. 25:1998;1938-1944.
21. Kaneko F., Takahashi Y., Muramatsu R., Adachi K., Nakane A., Minagawa T. Natural killer cell numbers and function in peripheral lymphoid cells in Behçet's disease. Br J Dermatol. 113:1985;313-318.
22. Yamashita N. Hyperreactivity of neutrophils and abnormal T cell homeostasis: a new insight for pathogenesis of Behçet's disease. Int Rev Immunol. 14:1997;11-19.
23. Criteria for diagnosis of Behçet's disease. Lancet. 335:1990;1078-1080.
24. Yazici H., Pazarli H., Barnes C.G., et al A. controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 322:1990;281-285.
25. Demiroglu H., Barista I., Dündar S. Risk factor assessment and prognosis of eye involvement in Behçet's disease in Turkey. Ophthalmology. 104:1997;701-705.
26. Dinning W.J. An overview of ocular manifestations. Lehner T., Barnes C.G. Recent advances in Behçet's disease. 1986;227-233.
27. Hamuryudan V., Özyazgan Y., Hizli N.et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum. 40:1997;769-774.
28. Masuda K., Urayama A., Kogure M., Nakajima A., Nakae K., Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet. I:1989;1093-1096.
29. Guyer D.R., Tiedeman J., Yannuzzi L.A.et al. Interferon-associated retinopathy. Arch Ophthalmol. 111:1993;350-356.
30. Edwards B.S., Merritt J.A., Fuhlbrigge R.C., Borden E.C. Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest. 75:1985;1908-1913.
31. Azizlerli G., Sarica R., Köse A.et al. The long-term treatment with interferon alpha-2a in Behçet's disease. Hamza M. Behçet's disease. 1997;453-455 Pub Adhoua, Tunis.
32. Antonelli G., Currenti M., Turriziani O., Dianzani F. Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J Infect Dis. 163:1991;882-885.